City of Hope Medical Center
This phase II trial tests how well giving zanubrutinib and sonrotoclax works for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) that has come back after a period of improvement (relapsed). Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) and BCL-XL inhibitors. It may stop the growth of tumor cells and may kill them by blocking Bcl-2 and Bcl-XL, proteins needed for cell survival. Giving zanubrutinib and sonrotoclax may work well for the treatment of relapsed CLL/SLL.
PRIMARY OBJECTIVE: I. Estimate overall response rate (ORR). SECONDARY OBJECTIVES: I. Estimate complete response (CR) rate. II. Estimate minimal residual disease (MRD) negativity by flow cytometry every 6 months. III. Estimate progression-free survival (PFS) at 2, 3, and 5 years. IV. Estimate duration of response (DOR) at 2, 3, and 5 years. V. Estimate overall survival (OS) at 2, 3, and 5 years. EXPLORATORY OBJECTIVES: I. Identify mechanisms of resistance. II. Evaluate effect of treatment on immune cell repertoire. III. Evaluate clinical outcome stratified by first line therapy (anti-CD20…
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative. * Assent, when appropriate, will be obtained per institutional guidelines * Age: ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) ≤ 2 * Histological or flow cytometry confirmed diagnosis of B-CLL/SLL as documented by medical records and with histology based on criteria established by the World Health Organization (WHO) * CLL has progressed at least 6 months after completion of first-line fixed-duration novel drug (non-chemotherapy) regimen, including but not limited to venet…
Undergo blood sample collection
Undergo bone marrow aspiration
Undergo bone marrow biopsy
Undergo CT scan
Undergo lymph node biopsy
Undergo MRI
Given PO
Given PO